[go: up one dir, main page]

EP1221965A1 - Use of tgf beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa - Google Patents

Use of tgf beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa

Info

Publication number
EP1221965A1
EP1221965A1 EP00971890A EP00971890A EP1221965A1 EP 1221965 A1 EP1221965 A1 EP 1221965A1 EP 00971890 A EP00971890 A EP 00971890A EP 00971890 A EP00971890 A EP 00971890A EP 1221965 A1 EP1221965 A1 EP 1221965A1
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
tgf
fibres
use according
igf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP00971890A
Other languages
German (de)
French (fr)
Inventor
Maarten Anne Hoijer
Robert Johan Joseph Hageman
Rudolf Leonardus Lodewijk Smeets
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Campina Melkune BV
Nutricia NV
Original Assignee
Campina Melkune BV
Nutricia NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Campina Melkune BV, Nutricia NV filed Critical Campina Melkune BV
Priority to EP07100978A priority Critical patent/EP1779863A1/en
Publication of EP1221965A1 publication Critical patent/EP1221965A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals

Definitions

  • the present invention relates to the use of a composition containing transforming growth factor ⁇ (TGF- ⁇ ) and a composition containing anabolic growth factors (AGF), in particular insulin-like growth factor 1 (IGF-1) for the prevention or treatment of malfunction or disease of the intestinal mucosa.
  • TGF- ⁇ transforming growth factor ⁇
  • AMF anabolic growth factors
  • IGF-1 insulin-like growth factor 1
  • the invention further relates to a composition containing TGF- ⁇ and specific fibres and/or immunoglobulines and/or calcium which can also be used for such a treatment, in particular in combination with IGF-1.
  • the composition containing TGF- ⁇ is administered during a period in which it is desired to inhibit cell proliferation and stimulate cell differentiation.
  • the composition containing IGF-1 is administered to restore intestinal epithelial cells.
  • TGF- ⁇ is a multifunctional protein found in all mammalian tissues. Currently, five forms of TGF- ⁇ are known, ⁇ l to ⁇ 5. It has been implicated in the development, differentiation and growth of tissue and the control of immune system function and carcinogenesis. TGF- ⁇ can be isolated from natural sources (e.g. blood platelets), mammalian milk or colostrum or can be produced by recombinant cells.
  • natural sources e.g. blood platelets
  • mammalian milk or colostrum can be produced by recombinant cells.
  • IGF-1 is a small protein (molecular weight about 7800) which plays an important role in bone metabolism. It has been shown to stimulate growth of cells in culture. Animal growth is also stimulated in pituitary deficient, normal and catabolic states. Kidney function is also improved. It can be produced using recombinant DNA technology, solid phase peptide synthesis, by isolating it from blood serum or from human or bovine milk.
  • TGF- ⁇ and its uses are for instance described in EP 852913.
  • This document relates to an enteral food preparation which contains casein rich in TGF- ⁇ 2, a lipid source such as medium chain or long chain triglycerides or polyunsaturated fatty acids and a carbohydrate source, i.e. maltodextrin, corn starch or sucrose.
  • This composition is used in the treatment or prophylaxis of inflammatory conditions of the gastrointestinal tract, such as Crohn's disease.
  • EP 462,398 describes the combination of TGF- ⁇ 1 and a polyunsaturated fatty acid (PUFA) such as linoleic acid, alpha-linolenic acid, gamma-linolenic acid, arachidonic acid, dihomo- gamma-linolenic acid, eicosapentaenoic acid and/or docosahexanoic acid and/or a derivative thereof for treatment of neoplastic diseases.
  • PUFA polyunsaturated fatty acid
  • WO 96/34614 describes a method for preventing and/or treating damage to the lining of the alimentary tract resulting from chemotherapy and/or radiation, wherein a milk product extract including a mixture of cell growth factors is administered to a patient.
  • the milk product extract preferably a cheese whey extract, may contain lactoferrin and lactoperoxidase and it can be supplemented with growth factors such as IGF-1, IGF-2, TGF- ⁇ , TGF- ⁇ , EGF, PDGF, FGF or KGF. This document does not mention which of the substances mentioned should be present in order to achieve the desired preventing or curing effect.
  • TGF- ⁇ 3 Treatment of chemotherapy induced ulcerative mucositis by transforming growth factor ⁇ 3
  • Topical application of TGF- ⁇ 3 to the oral mucosa of the Syrian golden hamster prior to chemotherapy significantly reduced the incidence, severity and duration of oral mucositis, reduced chemotherapy associated weight loss and increased survival.
  • Prevention of mucositis according to this document is based on limiting the rate of basal epithelial cell proliferation by prior administration of a negative growth regulator.
  • TGF- ⁇ 3 can be administered to slow growth of normal cells and thereby inhibit cytotoxic poisoning of the normal cells in the subject.
  • the TGF- ⁇ 3 is administered prior to anti-neoplastic therapy.
  • a mitogen for epithelial cells can be administered.
  • the drawback of the method of this document is that preferably a growth factor obtained by recombinant technology is used.
  • these type of growth factors have shown to be less stable during sterilisation treatments. Also the biological availability of these growth factors in the gastrointestinal tract is not yet satisfactory.
  • TGF- ⁇ should be administered without the presence of IGF-1, in particular any anabolic growth factor, during the chemotherapy or radiotherapy.
  • IGF-1 in particular any anabolic growth factor
  • damaging effects that may have occurred during this therapy can be treated by administering anabolic growth factors, in particular IGF-1 in the substantial absence of TGF- ⁇ .
  • IBD inflammatory bowel diseases
  • the present invention therefore provides the use of TGF- ⁇ and AGF in the preparation of a product for use in the treatment and/or prevention of malfunction or disease of the intestinal mucosa; the product comprising: a) a first pharmaceutical composition comprising TGF- ⁇ in the substantial absence of IGF-1, which TGF- ⁇ is obtained by extraction from a mammalian milk product; b) a second pharmaceutical composition comprising AGF in the substantial absence of TGF- ⁇ , wherein the first and second composition are administered sequentially.
  • the weight ratio TGF- ⁇ /IGF-1 in the first pharmaceutical composition is at least 100.
  • TGF- ⁇ when a mixture of growth factors is used, for instance when a milk product extract is used, the beneficial effect of TGF- ⁇ is reduced by the presence of anabolic growth factors Therefore, it is preferred to administer TGF- ⁇ in the substantial absence of such growth factors.
  • the first pharmaceutical composition comprises TGF- ⁇ in substantial absence of AGF.
  • IGF-1 insulin-like growth factor 2
  • IGF-2 insulin-like growth factor 2
  • EGF epidermal growth factor
  • TGF- ⁇ transforming growth factor ⁇
  • MMGF mammalian milk growth factor
  • FGF fibroblast growth factor
  • EGF is for instance described in EP 0546 068, MMGF in WO 99/24470.
  • the ratio TGF- ⁇ /AGF is preferably at least 50.
  • the AGF in the second pharmaceutical composition is IGF-1. This means that preferably at least IGF- 1 is present in the second composition.
  • these include also the active peptide analogues of these growth factors.
  • peptide analogue is meant any peptide having substantially the same activity as the growth factor, particularly any peptide analogue which is 90% or more homologous with the growth factor.
  • “Pharmaceutical composition” is meant to include any conventional pharmaceutical preparation such as a capsule, a tablet etc., as well as dietetic preparations such as feed supplements or total feeds.
  • the sequential administration of the first pharmaceutical composition containing TGF- ⁇ and the second pharmaceutical composition containing AGF, preferably at least IGF-1, according to the invention is particular suitable for intestinal disorders in which two phases can be distinguished.
  • the first phase is a phase in which it is desired to inhibit the metabolism.
  • the second phase which follows the first phase, the intestinal epithelial cells need to be restored.
  • the composition containing TGF- ⁇ is administered during the first phase, the composition containing anabolic growth factors, in particular IGF-1 during the second phase.
  • the sequential administration of TGF- ⁇ and IGF-1 is used for the prevention and/or treatment of damage of the intestinal mucosa as a result of chemotherapy and/or radiotherapy.
  • damage is meant any alteration in normal structure or function. Such damage includes mucositis, at least partial loss of mucosal crypt area and/or mucosal villus length, or an increase in bacterial translocation across the alimentary tract.
  • Chemotherapy and/or radiotherapy are effective at destroying tumours because they target fast-growing tissues. While tumour cells are selectively targeted by anticancer treatments the fast growing tissues of the host are also susceptible, particularly the immune cells of the body and the lining of the alimentary tract. This can result in damage to the linings of the mouth and oesophagus (mucositis, also referred to as stomatitis) and damage to the intestinal lining, commonly in the small bowel and less frequently in the large bowel, leading to severe diarrhoea and pain.
  • mucositis also referred to as stomatitis
  • a first composition containing TGF- ⁇ should be administered without the presence of IGF-I, preferably any anabolic growth factor, during the chemotherapy or radiotherapy, in particular during at least the period starting at the latest the first day of said chemotherapy or radiotherapy treatment and ending at the latest the last day of treatment. It was furthermore found that after the chemotherapy or radiotherapy, damaging effects that may have occurred during these therapies can be treated by administering a second composition containing AGF, in particular IGF-1, in the substantial absence of TGF- ⁇ .
  • IGF-I preferably any anabolic growth factor
  • the sequential administration of TGF- ⁇ and IGF-1 is used in the prevention and/or treatment of inflammatory conditions of the intestine, in particular inflammatory bowel diseases (IBD), such as Crohn's disease.
  • IBD inflammatory bowel diseases
  • TGF- ⁇ a TGF- ⁇ extracted from a mammalian milk product, such as milk or whey, in particular bovine milk or whey, most preferably whey is used.
  • a mammalian milk product such as milk or whey, in particular bovine milk or whey, most preferably whey is used.
  • the advantages of such TGF- ⁇ are that it comes from a natural source because of the reluctance against products obtained by recombinant techniques, cost effectiveness and the presence of other beneficial components in milk or whey extract, such as immunoglobulins.
  • Milk contains TGF- ⁇ l(ca. 15%) and TGF- ⁇ 2 (ca. 85%).
  • a process for extracting such a TGF- ⁇ is described in a copending application of the applicants (PCT NL/99/00621).
  • an extract which contains binding factors for TGF- ⁇ .
  • This extract can be obtained by using an extraction process, preferably excluding acidic extraction steps (pH ⁇ 5.5).
  • Binding factors for TGF- ⁇ are defined as components that are able to form a stable complex with TGF- ⁇ in aqueous media. In bovine milk these are albumin and Latency Associated Peptide (LAP).
  • binding factors results in increased stability of the growth factor, for instance during sterilisation. It also results in better bioavailability of TGF- ⁇ and thus in higher activity.
  • the binding factors help survive the growth factors during passage in the intestine, where digestive enzymes may degrade the growth factors resulting in (partial) loss of activity.
  • milk products could be used as a source for growth factors in the treatment of the disorders as mentioned in the present application, but that in order to be useful a separation treatment should be carried out, separating the transforming growth factor from anabolic growth factors.
  • a TGF- ⁇ obtained from bovine whey or milk will in general contain more than 100, preferably more than 700 ⁇ g TGF- ⁇ per g protein. Such an extract will for instance contain 750 ⁇ g TGF- ⁇ /g protein.
  • the IGF-1 content in this extract will be less than 4, preferably less than 1 ⁇ g/g protein.
  • the TGF- ⁇ is present in the composition in such an amount that 50 ng to 150 ⁇ g per day is administered. In case of a liquid product, this will contain TGF- ⁇ in a concentration of 0.5 ⁇ g -1.5 mg TGF- ⁇ per litre. The patient will be administered about 100 ml per day of such a liquid product.
  • the first pharmaceutical composition according to the invention also con- tains fibres which upon fermentation form more than 15 g of butyrate per 100 g of short chain fatty acids, preferably more than 20 g of butyrate per 100 g of short chain fatty acids.
  • This characteristic means that the composition should contain fibres that release a relative large amount of butyrate when they are fermented in the intestine (colon). The amount of butyrate can be determined by the method described in Journal of Clinical Nutrition, 1991, no. 53, p. 1418-1424.
  • fibres which upon fermentation result in butyrate.
  • Such fibres are: resistant starch, oats bran, in particular the arabinoxylan rich fraction that is poor in ⁇ -glucan, some soy fibre extracts and wheat bran.
  • wheat bran is used.
  • the amount of fibre is such that a daily ratio of 1 to 30 g, preferably 3 to 10 g, is obtained. In a liquid preparation the concentration is thus 10 to 300 g/1.
  • the TGF- ⁇ composition according to the invention preferably contains immunoglobulins, more in particular in combination with the above mentioned fibres. Their main function is to interact with harmful micro-organisms such as bacteria. This prevents the micro-organism from entering the blood circulation system. This situation in particular occurs when the intestinal mucosa of the patient has been damaged as a result of treatment with chemotherapy.
  • the immunoglobulins can be isolated from milk of mammals which have been hyperimmu- nised against certain pathogens or they can be isolated from normal bovine whey or milk. With the process described in the above mentioned patent application, using normal cow's milk as a starting material, a preparation is obtained rich in IgG and IgA. 30 to 50 % of the protein fraction consists of immunoglobulins of the type IgG and IgA. The concentration immunoglobulins in the preparation will, in case of a liquid preparation of 100 ml, be 0.1 to 1500 mg/1.
  • the TGF- ⁇ composition contains calcium, preferably in combination with the above mentioned fibres, more preferably in combination with said fibres and immunoglobulins.
  • the calcium can be in the form of finely dispersed calcium phosphate, calcium carbonate, calcium citrate or a calcium concentrate from bovine milk.
  • the addition of calcium reduces the risk of infection. Calcium lowers the proliferation rate of the epithelial cells.
  • the amount of calcium is more than 50 mg/100 ml, preferably more than 100 mg/100 ml, for instances 120 mg/100 ml, based on a liquid composition.
  • the first pharmaceutical composition containing TGF- ⁇ according to the invention also contains one or more of the following ingredients: proteins, fat, minerals, trace elements, vitamins, fatty acids and lactoferrin.
  • proteins are present in an amount of 3 to 10 % protein equivalents, this includes intact protein, peptides and amino acids.
  • the amount of fat is preferably 2 to 10 %, based on the total weight of the preparation.
  • the amount of minerals, trace elements and vitamins is according to the daily recommended dosage.
  • Vitamin A is vitamin A, C and E.
  • Vitamin A and provitamin A are required. Their concentration is preferably more than 130 ⁇ gRE/100 ml, in particular more than 300 ⁇ g/100 ml.
  • part of the vitamin A is administered as retinoic acid or a metabolic equivalent thereof.
  • Vitamin C and tocopherols are administered because of their role in the antioxidant cascade. During radiotherapy but also with initial inflammatory reactions they can protect the epithelial cells.
  • the concentration vitamin C or an equivalent thereof is more than 40 mg/100 ml, preferably more than 60 mg/100 ml.
  • the concentration of tocopherols is more than 5 mg, preferably more than 15 mg/100 ml.
  • the fats should provide sufficient fatty acids.
  • stearidonic acid STA
  • Suitable fatty acids and the amounts and ratios in which they are used are described in PCT/EP98/08409, i.e. the fatty acids gamma-linolenic acid, stearidonic acid and eicosapentaenoic acid together constitute 10 to 500 mg/g of the total amount of fatty acids and gamma-linolenic acid and eicosapentaenoic constitute 20 to 50 wt.% and stearidonic acid forms 15 to 50 wt.% of these three fatty acids.
  • Lactoferrin can be present because it has anti-bacterial activity against a number of pathogens. This substance can also have a modulating action with initial inflammatory reactions, which are delayed. It is desired to have a daily doses of 0.1 to 3 g of lactoferrin. It is preferred that the composition contains less than 11 %, preferably less than 6 % digestible carbohydrates. A higher percentage of these substances would affect the taste of the composition. Generally about 4.5 g/100 ml are used. As a source of digestible carbohydrates sucrose, but also slowly digestible carbohydrates can be used.
  • the dosage of IGF-1 is preferably 0.1 to 100 ⁇ g IGF-1 per kg body weight per day. In a liquid product this concentration is 7 ⁇ g to 7 mg IGF-1 per 100 ml.
  • the second composition preferably contains substantially no TGF- ⁇ .
  • the ratio IGF-1/TGF- ⁇ is at least 50, preferably at least 100.
  • the IGF-1 according to the invention is preferably obtained by extraction from a mammalian milk product, such as milk or whey, in particular bovine milk or whey, most preferably whey. Such an extraction is shown in the copending application of the applicants (PCT/NL/99/00621).
  • the second composition can further contain immunoglobulins.
  • immunoglobulins In view of the severity of the mucositis which has developed, it is important to prevent and/or treat translocation of harmful substances, for instance micro-organisms. Preferably doses of 0.03 mg to 5 mg immunoglobulins per day are administered. If the IGF-1 is obtained from bovine milk, generally a preparation will be obtained containing 10 to 1000 mg Ig per 100 ⁇ g IGF-1.
  • fibres can be present.
  • a mixture of fibres is preferably administered.
  • theses fibres are soluble non-starch polysaccharides, such as gum arabic or pectin, insoluble non-starch polysaccharides, such as cellulose and hemicel- lulose and oligosaccharides and/or resistant starch and/or lignin.
  • soluble non-starch polysaccharides such as gum arabic or pectin
  • insoluble non-starch polysaccharides such as cellulose and hemicel- lulose and oligosaccharides and/or resistant starch and/or lignin.
  • the second composition can further contain one or more of lactoferrin, glutamine and anti- oxidants.
  • Glutamine must have a stable form.
  • glutamine rich peptides should be used or extracts from hydrolysates of glutamine rich proteins.
  • the amounts of lactoferrin and antioxidants are the same as in the first composition.
  • the second composition may contain fat, protein and other microcomponents, such as minerals, vitamins and trace elements. Further, substances that support the total methionin metabolism can be present.
  • TGF- ⁇ in the substantial absence of insulin-like growth factor 1 IGF-1, in particular in the absence of AGF, and fibres which upon fermentation form more than 15 g of butyrate per lOOg of short chain fatty acids and/or immunoglobulins are used for preparing a pharmaceutical composition for treatment and/or prevention of malfunction or disease of the intestinal mucosa, more in particular for treatment and/or prevention of damage of the intestinal mucosa as a result of chemotherapy or radiotherapy or for treatment and/or prevention of inflammatory bowel diseases.
  • the present invention also relates to a pharmaceutical composition containing TGF- ⁇ in the substantial absence of IGF-1, in particular in the absence of AGF, preferably in combination with fibres which upon fermentation form more than 15 g of butyrate per 100 g of short chain fatty acids and/or immunoglobulins.
  • such a composition contains per 100 ml a) 50 ng to 150 ⁇ g TGF- ⁇ b) 1 to 30 g fibres c) 0.01 to 150 mg immunoglobulins d) 0.03 to 1 g lactoferrin e) > 50 mg calcium f) fatty acids g) > 130 ⁇ g RE vitamin A h) > 40 mg vitamin C i) > 5 mg tocopherols j) 3 to 10% protein equivalents
  • a suitable liquid TGF- ⁇ based formula contains per 100 ml: a) 4 ⁇ g TGF- ⁇ b) 5 g wheat bran c) 2 mg immunoglobulins d) 0.5 g lactoferrin e) 80 mg calcium f) 4 g fat blend containing 30 % MCT, 26 % palm oil, 16 % soy oil, 8 % borage oil, 11.% echium oil, 6.5 % fish oil and 2.5 % egg lipids g) 300 ⁇ g vitamin A h) 70 mg vitamin C i) 15 mg ⁇ -tocopherol j) 4 g casein k) 5 g maltodextrin Of this formula, 250 ml per day is administered.
  • the invention also relates to a pharmaceutical composition containing AGF, preferably IGF- 1, in the substantial absence of TGF- ⁇ and fibres selected from soluble non-starch polysaccharides, such as gum arabic or pectin, insoluble non-starch polysaccharides, such as cellulose and hemicellulose and oligosaccharides and/or resistant starch and/or lignin.
  • AGF preferably IGF- 1
  • soluble non-starch polysaccharides such as gum arabic or pectin
  • insoluble non-starch polysaccharides such as cellulose and hemicellulose and oligosaccharides and/or resistant starch and/or lignin.
  • the composition preferably further contains at least one member of the group comprising lactoferrin, glutamine and antioxidants.
  • such a composition contains per 100 ml: a) 7 ⁇ g to 7 mg IGF-l b) 1 to 30 g fibres c) 5 to 300 mg immunoglobulins d) 0.3 to 3 g lactoferrin e) 0.5 to 10 g glutamine f) > 130 ⁇ g RE vitamin A g) > 40 mg vitamin C h) > 5 mg tocopherols
  • a suitable liquid IGF-1 based formula contains per 100 ml: a) 100 ⁇ g IGF-1 b) 5 g fibre mix: lg wheat bran, 3 g inulin, 1 g oats bran c) 200 mg immunoglobulins d) 0.5 g bovine lactoferrin e) 5 g alanylglutamine f) 300 ⁇ g vitamin A g) 70 mg vitamin C h) 15 mg ⁇ -tocopherol Of this formula, 250 ml per day is administered.
  • compositions according to the invention can have the form of any oral preparation, for instance capsules, sachets or tablets each containing a predetermined amount of the active ingredient; powders or granules; solutions or suspensions in an aqueous or non-aqueous liquid.
  • Preferred dosage forms are food supplements or total feeds or powders which upon reconstitution with a liquid such as water give a total feed or food supplement.
  • the present invention also relates to tube feeds containing these ingredients.
  • the present invention also relates to products consisting of a combination of the first compo- sition and the second composition for sequential administration for preventing and/or treating damage of the intestinal mucosa as a result of chemotherapy or radiotherapy or for preventing and/or treating inflammatory conditions of the intestine, in particular Crohn's disease.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to the use of transforming growth factor β (TGF-β) and anabolic growth factors (AGF) in the treatment and/or prevention of malfunction or disease of the intestinal mucosa. More in particular the invention relates to the treatment and/or prevention of damage of the intestinal mucosa as a result of chemotherapy of radiotherapy or of inflammatory bowel diseases with a product comprising: a) a first pharmaceutical composition comprising TGF-β obtained by extraction from a mammalian milk product in the substantial absence of insulin-like growth factor-1 (IGF-1); b) a second pharmaceutical composition comprising AGF in the substantial absence of TGF-β; wherein the first and second composition are administered sequentially.

Description

USE OF TGF BETA AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA
The present invention relates to the use of a composition containing transforming growth factor β (TGF-β) and a composition containing anabolic growth factors (AGF), in particular insulin-like growth factor 1 (IGF-1) for the prevention or treatment of malfunction or disease of the intestinal mucosa. The invention further relates to a composition containing TGF-β and specific fibres and/or immunoglobulines and/or calcium which can also be used for such a treatment, in particular in combination with IGF-1. The composition containing TGF-β is administered during a period in which it is desired to inhibit cell proliferation and stimulate cell differentiation. The composition containing IGF-1 is administered to restore intestinal epithelial cells.
TGF-β is a multifunctional protein found in all mammalian tissues. Currently, five forms of TGF-β are known, βl to β5. It has been implicated in the development, differentiation and growth of tissue and the control of immune system function and carcinogenesis. TGF-β can be isolated from natural sources (e.g. blood platelets), mammalian milk or colostrum or can be produced by recombinant cells.
IGF-1 is a small protein (molecular weight about 7800) which plays an important role in bone metabolism. It has been shown to stimulate growth of cells in culture. Animal growth is also stimulated in pituitary deficient, normal and catabolic states. Kidney function is also improved. It can be produced using recombinant DNA technology, solid phase peptide synthesis, by isolating it from blood serum or from human or bovine milk.
TGF-β and its uses are for instance described in EP 852913. This document relates to an enteral food preparation which contains casein rich in TGF-β2, a lipid source such as medium chain or long chain triglycerides or polyunsaturated fatty acids and a carbohydrate source, i.e. maltodextrin, corn starch or sucrose. This composition is used in the treatment or prophylaxis of inflammatory conditions of the gastrointestinal tract, such as Crohn's disease.
EP 462,398 describes the combination of TGF-β 1 and a polyunsaturated fatty acid (PUFA) such as linoleic acid, alpha-linolenic acid, gamma-linolenic acid, arachidonic acid, dihomo- gamma-linolenic acid, eicosapentaenoic acid and/or docosahexanoic acid and/or a derivative thereof for treatment of neoplastic diseases.
WO 96/34614 describes a method for preventing and/or treating damage to the lining of the alimentary tract resulting from chemotherapy and/or radiation, wherein a milk product extract including a mixture of cell growth factors is administered to a patient. The milk product extract, preferably a cheese whey extract, may contain lactoferrin and lactoperoxidase and it can be supplemented with growth factors such as IGF-1, IGF-2, TGF-β, TGF-α, EGF, PDGF, FGF or KGF. This document does not mention which of the substances mentioned should be present in order to achieve the desired preventing or curing effect.
In an article of S.T. Sonis et al, Cancer Res. 54: 1135-1 138 (1994); "Prevention of chemotherapy induced ulcerative mucositis by transforming growth factor β3" it is described that TGF-β3 administration reduced proliferation of oral epithelium in vitro and in vivo. Topical application of TGF-β3 to the oral mucosa of the Syrian golden hamster prior to chemotherapy significantly reduced the incidence, severity and duration of oral mucositis, reduced chemotherapy associated weight loss and increased survival. Prevention of mucositis according to this document is based on limiting the rate of basal epithelial cell proliferation by prior administration of a negative growth regulator.
US 5,842,297 describes that TGF-β3 can be administered to slow growth of normal cells and thereby inhibit cytotoxic poisoning of the normal cells in the subject. Typically the TGF-β3 is administered prior to anti-neoplastic therapy. It is further suggested that after neoplastic therapy a mitogen for epithelial cells can be administered. The drawback of the method of this document is that preferably a growth factor obtained by recombinant technology is used. However, these type of growth factors have shown to be less stable during sterilisation treatments. Also the biological availability of these growth factors in the gastrointestinal tract is not yet satisfactory.
It was found according to the invention that for optimum protection of the intestinal mucosa against the damaging effect of chemotherapy and radiotherapy TGF-β should be administered without the presence of IGF-1, in particular any anabolic growth factor, during the chemotherapy or radiotherapy. The use of a TGF-β obtained from extraction from a mammalian milk product appeared to result in better bioavailability of the growth factor and also increased stability. It was furthermore found that after the chemotherapy or radiotherapy, damaging effects that may have occurred during this therapy can be treated by administering anabolic growth factors, in particular IGF-1 in the substantial absence of TGF-β. According to the invention it was also found that the same sequential administration of TGF-β and IGF-1 can be beneficial in case of inflammatory bowel diseases (IBD), such as Crohn's disease.
The present invention therefore provides the use of TGF-β and AGF in the preparation of a product for use in the treatment and/or prevention of malfunction or disease of the intestinal mucosa; the product comprising: a) a first pharmaceutical composition comprising TGF-β in the substantial absence of IGF-1, which TGF-β is obtained by extraction from a mammalian milk product; b) a second pharmaceutical composition comprising AGF in the substantial absence of TGF- β, wherein the first and second composition are administered sequentially.
Preferably, the weight ratio TGF-β/IGF-1 in the first pharmaceutical composition is at least 100.
It has been found that when a mixture of growth factors is used, for instance when a milk product extract is used, the beneficial effect of TGF-β is reduced by the presence of anabolic growth factors Therefore, it is preferred to administer TGF-β in the substantial absence of such growth factors.
According to a preferred embodiment of the invention the first pharmaceutical composition comprises TGF-β in substantial absence of AGF. With AGF any anabolic growth factor is meant, i.e any growth factor that would promote cell growth. Examples thereof are: IGF-1, insulin-like growth factor 2 (IGF-2), growth hormone, epidermal growth factor (EGF), transforming growth factor α (TGF-α), mammalian milk growth factor (MMGF = Beta- cellulin) and fibroblast growth factor (FGF). EGF is for instance described in EP 0546 068, MMGF in WO 99/24470. The ratio TGF-β/AGF is preferably at least 50. Preferably, the AGF in the second pharmaceutical composition is IGF-1. This means that preferably at least IGF- 1 is present in the second composition.
According to the present invention when growth factors are mentioned, these include also the active peptide analogues of these growth factors. With peptide analogue is meant any peptide having substantially the same activity as the growth factor, particularly any peptide analogue which is 90% or more homologous with the growth factor.
"Pharmaceutical composition" according to the present invention is meant to include any conventional pharmaceutical preparation such as a capsule, a tablet etc., as well as dietetic preparations such as feed supplements or total feeds.
The sequential administration of the first pharmaceutical composition containing TGF-β and the second pharmaceutical composition containing AGF, preferably at least IGF-1, according to the invention is particular suitable for intestinal disorders in which two phases can be distinguished. The first phase is a phase in which it is desired to inhibit the metabolism. During the second phase, which follows the first phase, the intestinal epithelial cells need to be restored. The composition containing TGF-β is administered during the first phase, the composition containing anabolic growth factors, in particular IGF-1 during the second phase.
More in particular, the sequential administration of TGF-β and IGF-1 is used for the prevention and/or treatment of damage of the intestinal mucosa as a result of chemotherapy and/or radiotherapy. By "damage" is meant any alteration in normal structure or function. Such damage includes mucositis, at least partial loss of mucosal crypt area and/or mucosal villus length, or an increase in bacterial translocation across the alimentary tract.
Chemotherapy and/or radiotherapy are effective at destroying tumours because they target fast-growing tissues. While tumour cells are selectively targeted by anticancer treatments the fast growing tissues of the host are also susceptible, particularly the immune cells of the body and the lining of the alimentary tract. This can result in damage to the linings of the mouth and oesophagus (mucositis, also referred to as stomatitis) and damage to the intestinal lining, commonly in the small bowel and less frequently in the large bowel, leading to severe diarrhoea and pain. It was found according to the invention that for optimum protection of the intestinal mucosa against the damaging effect of chemotherapy and radiotherapy a first composition containing TGF-β should be administered without the presence of IGF-I, preferably any anabolic growth factor, during the chemotherapy or radiotherapy, in particular during at least the period starting at the latest the first day of said chemotherapy or radiotherapy treatment and ending at the latest the last day of treatment. It was furthermore found that after the chemotherapy or radiotherapy, damaging effects that may have occurred during these therapies can be treated by administering a second composition containing AGF, in particular IGF-1, in the substantial absence of TGF-β.
According to a further embodiment of the invention the sequential administration of TGF-β and IGF-1 is used in the prevention and/or treatment of inflammatory conditions of the intestine, in particular inflammatory bowel diseases (IBD), such as Crohn's disease.
As the TGF-β to be used according to the present invention, a TGF-β extracted from a mammalian milk product, such as milk or whey, in particular bovine milk or whey, most preferably whey is used. The advantages of such TGF-β are that it comes from a natural source because of the reluctance against products obtained by recombinant techniques, cost effectiveness and the presence of other beneficial components in milk or whey extract, such as immunoglobulins. Milk contains TGF-βl(ca. 15%) and TGF-β2 (ca. 85%). A process for extracting such a TGF-β is described in a copending application of the applicants (PCT NL/99/00621).
Preferably an extract is used which contains binding factors for TGF-β. This extract can be obtained by using an extraction process, preferably excluding acidic extraction steps (pH < 5.5). Binding factors for TGF-β are defined as components that are able to form a stable complex with TGF-β in aqueous media. In bovine milk these are albumin and Latency Associated Peptide (LAP).
The presence of binding factors results in increased stability of the growth factor, for instance during sterilisation. It also results in better bioavailability of TGF-β and thus in higher activity. The binding factors help survive the growth factors during passage in the intestine, where digestive enzymes may degrade the growth factors resulting in (partial) loss of activity.
One of the important findings of the present inventors was that milk products could be used as a source for growth factors in the treatment of the disorders as mentioned in the present application, but that in order to be useful a separation treatment should be carried out, separating the transforming growth factor from anabolic growth factors.
A TGF-β obtained from bovine whey or milk will in general contain more than 100, preferably more than 700 μg TGF-β per g protein. Such an extract will for instance contain 750 μg TGF-β/g protein. The IGF-1 content in this extract will be less than 4, preferably less than 1 μg/g protein.
Preferably the TGF-β is present in the composition in such an amount that 50 ng to 150 μg per day is administered. In case of a liquid product, this will contain TGF-β in a concentration of 0.5 μg -1.5 mg TGF-β per litre. The patient will be administered about 100 ml per day of such a liquid product.
It is preferred that the first pharmaceutical composition according to the invention also con- tains fibres which upon fermentation form more than 15 g of butyrate per 100 g of short chain fatty acids, preferably more than 20 g of butyrate per 100 g of short chain fatty acids. This characteristic means that the composition should contain fibres that release a relative large amount of butyrate when they are fermented in the intestine (colon). The amount of butyrate can be determined by the method described in Journal of Clinical Nutrition, 1991, no. 53, p. 1418-1424.
Certain disorders of gut function, for instance resulting from chemotherapy can influence the intestinal flora, which causes a temporary decrease of the fermentation to butyrate, in particular in those cases that the patient is also given a large amount of antibiotics. It is therefore important to administer fibres to the patient which stimulate the synthesis of butyrate by bacteria whereby more butyrate is released into the intestine. Butyrate is a preferential energy substrate in certain intestinal cells, and it also inhibits proliferation and increases differentiation of these cells. If butyrate is administered as its free salt, undesirable off-flavours can occur. Further only part of the butyrate would reach the colon. A sustained release preparation could overcome this problem, however, these preparations are relatively expensive.
Therefore, according to the present invention it is proposed to administer specific fibres which upon fermentation result in butyrate. Such fibres are: resistant starch, oats bran, in particular the arabinoxylan rich fraction that is poor in β-glucan, some soy fibre extracts and wheat bran. Preferably, wheat bran is used. The amount of fibre is such that a daily ratio of 1 to 30 g, preferably 3 to 10 g, is obtained. In a liquid preparation the concentration is thus 10 to 300 g/1.
The TGF-β composition according to the invention preferably contains immunoglobulins, more in particular in combination with the above mentioned fibres. Their main function is to interact with harmful micro-organisms such as bacteria. This prevents the micro-organism from entering the blood circulation system. This situation in particular occurs when the intestinal mucosa of the patient has been damaged as a result of treatment with chemotherapy.
The immunoglobulins can be isolated from milk of mammals which have been hyperimmu- nised against certain pathogens or they can be isolated from normal bovine whey or milk. With the process described in the above mentioned patent application, using normal cow's milk as a starting material, a preparation is obtained rich in IgG and IgA. 30 to 50 % of the protein fraction consists of immunoglobulins of the type IgG and IgA. The concentration immunoglobulins in the preparation will, in case of a liquid preparation of 100 ml, be 0.1 to 1500 mg/1.
According to a further preferred embodiment the TGF-β composition contains calcium, preferably in combination with the above mentioned fibres, more preferably in combination with said fibres and immunoglobulins. The calcium can be in the form of finely dispersed calcium phosphate, calcium carbonate, calcium citrate or a calcium concentrate from bovine milk. The addition of calcium reduces the risk of infection. Calcium lowers the proliferation rate of the epithelial cells. The amount of calcium is more than 50 mg/100 ml, preferably more than 100 mg/100 ml, for instances 120 mg/100 ml, based on a liquid composition. It has been found that when a product containing TGF-β, butyrate producing fibres and high levels of calcium salts is administered a synergistic effect occurs resulting in a composition that is effective in preventing damage to epithelial gut cells during chemotherapy and radiotherapy and in the treatment of inflammatory bowel diseases.
Preferably, the first pharmaceutical composition containing TGF-β according to the invention also contains one or more of the following ingredients: proteins, fat, minerals, trace elements, vitamins, fatty acids and lactoferrin.
Preferably, proteins are present in an amount of 3 to 10 % protein equivalents, this includes intact protein, peptides and amino acids. The amount of fat is preferably 2 to 10 %, based on the total weight of the preparation. The amount of minerals, trace elements and vitamins is according to the daily recommended dosage.
Preferred vitamins are vitamin A, C and E. Vitamin A and provitamin A are required. Their concentration is preferably more than 130 μgRE/100 ml, in particular more than 300 μg/100 ml. Suitably part of the vitamin A is administered as retinoic acid or a metabolic equivalent thereof. Vitamin C and tocopherols are administered because of their role in the antioxidant cascade. During radiotherapy but also with initial inflammatory reactions they can protect the epithelial cells. The concentration vitamin C or an equivalent thereof is more than 40 mg/100 ml, preferably more than 60 mg/100 ml. The concentration of tocopherols is more than 5 mg, preferably more than 15 mg/100 ml.
The fats should provide sufficient fatty acids. Preferably stearidonic acid (STA) is added. Suitable fatty acids and the amounts and ratios in which they are used are described in PCT/EP98/08409, i.e. the fatty acids gamma-linolenic acid, stearidonic acid and eicosapentaenoic acid together constitute 10 to 500 mg/g of the total amount of fatty acids and gamma-linolenic acid and eicosapentaenoic constitute 20 to 50 wt.% and stearidonic acid forms 15 to 50 wt.% of these three fatty acids.
Lactoferrin can be present because it has anti-bacterial activity against a number of pathogens. This substance can also have a modulating action with initial inflammatory reactions, which are delayed. It is desired to have a daily doses of 0.1 to 3 g of lactoferrin. It is preferred that the composition contains less than 11 %, preferably less than 6 % digestible carbohydrates. A higher percentage of these substances would affect the taste of the composition. Generally about 4.5 g/100 ml are used. As a source of digestible carbohydrates sucrose, but also slowly digestible carbohydrates can be used.
In the second composition, the dosage of IGF-1 is preferably 0.1 to 100 μg IGF-1 per kg body weight per day. In a liquid product this concentration is 7 μg to 7 mg IGF-1 per 100 ml. The second composition preferably contains substantially no TGF-β. The ratio IGF-1/TGF-β is at least 50, preferably at least 100.
The IGF-1 according to the invention is preferably obtained by extraction from a mammalian milk product, such as milk or whey, in particular bovine milk or whey, most preferably whey. Such an extraction is shown in the copending application of the applicants (PCT/NL/99/00621).
The second composition can further contain immunoglobulins. In view of the severity of the mucositis which has developed, it is important to prevent and/or treat translocation of harmful substances, for instance micro-organisms. Preferably doses of 0.03 mg to 5 mg immunoglobulins per day are administered. If the IGF-1 is obtained from bovine milk, generally a preparation will be obtained containing 10 to 1000 mg Ig per 100 μg IGF-1.
Beside immunoglobulins, fibres can be present. As this composition is administered during a phase wherein the intestinal flora of the patient is extremely disrupted, a mixture of fibres is preferably administered. Preferably theses fibres are soluble non-starch polysaccharides, such as gum arabic or pectin, insoluble non-starch polysaccharides, such as cellulose and hemicel- lulose and oligosaccharides and/or resistant starch and/or lignin. An example of such a mixture is described in EP 0756828, which is incorporated by reference.
The second composition can further contain one or more of lactoferrin, glutamine and anti- oxidants. Glutamine must have a stable form. In a liquid product, glutamine rich peptides should be used or extracts from hydrolysates of glutamine rich proteins. The amounts of lactoferrin and antioxidants are the same as in the first composition. Further the second composition may contain fat, protein and other microcomponents, such as minerals, vitamins and trace elements. Further, substances that support the total methionin metabolism can be present.
According to a further embodiment of the invention TGF-β in the substantial absence of insulin-like growth factor 1 IGF-1, in particular in the absence of AGF, and fibres which upon fermentation form more than 15 g of butyrate per lOOg of short chain fatty acids and/or immunoglobulins are used for preparing a pharmaceutical composition for treatment and/or prevention of malfunction or disease of the intestinal mucosa, more in particular for treatment and/or prevention of damage of the intestinal mucosa as a result of chemotherapy or radiotherapy or for treatment and/or prevention of inflammatory bowel diseases.
The present invention also relates to a pharmaceutical composition containing TGF-β in the substantial absence of IGF-1, in particular in the absence of AGF, preferably in combination with fibres which upon fermentation form more than 15 g of butyrate per 100 g of short chain fatty acids and/or immunoglobulins.
In case of a liquid composition, such a composition contains per 100 ml a) 50 ng to 150 μg TGF-β b) 1 to 30 g fibres c) 0.01 to 150 mg immunoglobulins d) 0.03 to 1 g lactoferrin e) > 50 mg calcium f) fatty acids g) > 130 μg RE vitamin A h) > 40 mg vitamin C i) > 5 mg tocopherols j) 3 to 10% protein equivalents
For example, a suitable liquid TGF-β based formula contains per 100 ml: a) 4 μg TGF-β b) 5 g wheat bran c) 2 mg immunoglobulins d) 0.5 g lactoferrin e) 80 mg calcium f) 4 g fat blend containing 30 % MCT, 26 % palm oil, 16 % soy oil, 8 % borage oil, 11.% echium oil, 6.5 % fish oil and 2.5 % egg lipids g) 300 μg vitamin A h) 70 mg vitamin C i) 15 mg α-tocopherol j) 4 g casein k) 5 g maltodextrin Of this formula, 250 ml per day is administered.
The invention also relates to a pharmaceutical composition containing AGF, preferably IGF- 1, in the substantial absence of TGF-β and fibres selected from soluble non-starch polysaccharides, such as gum arabic or pectin, insoluble non-starch polysaccharides, such as cellulose and hemicellulose and oligosaccharides and/or resistant starch and/or lignin. The composition preferably further contains at least one member of the group comprising lactoferrin, glutamine and antioxidants.
In case of a liquid composition, such a composition contains per 100 ml: a) 7 μg to 7 mg IGF-l b) 1 to 30 g fibres c) 5 to 300 mg immunoglobulins d) 0.3 to 3 g lactoferrin e) 0.5 to 10 g glutamine f) > 130 μg RE vitamin A g) > 40 mg vitamin C h) > 5 mg tocopherols
For example, a suitable liquid IGF-1 based formula contains per 100 ml: a) 100 μg IGF-1 b) 5 g fibre mix: lg wheat bran, 3 g inulin, 1 g oats bran c) 200 mg immunoglobulins d) 0.5 g bovine lactoferrin e) 5 g alanylglutamine f) 300 μg vitamin A g) 70 mg vitamin C h) 15 mg α-tocopherol Of this formula, 250 ml per day is administered.
The compositions according to the invention can have the form of any oral preparation, for instance capsules, sachets or tablets each containing a predetermined amount of the active ingredient; powders or granules; solutions or suspensions in an aqueous or non-aqueous liquid. Preferred dosage forms are food supplements or total feeds or powders which upon reconstitution with a liquid such as water give a total feed or food supplement. The present invention also relates to tube feeds containing these ingredients.
The present invention also relates to products consisting of a combination of the first compo- sition and the second composition for sequential administration for preventing and/or treating damage of the intestinal mucosa as a result of chemotherapy or radiotherapy or for preventing and/or treating inflammatory conditions of the intestine, in particular Crohn's disease.

Claims

Claims
1. Use of transforming growth factor β (TGF-β) and anabolic growth factors (AGF) in the preparation of a product for use in the treatment and/or prevention of malfunction or disease of the intestinal mucosa; the product comprising a) a first pharmaceutical composition comprising TGF-β in the substantial absence of insulin-like growth factor-1 (IGF-1) which TGF-β is obtained by extraction from a mammalian milk product; b) a second pharmaceutical composition comprising AGF in the substantial absence of TGF- β; wherein the first and second composition are administered sequentially.
2. Use according to claim 1, wherein the mammalian milk product is bovine milk or whey, preferably whey.
3. Use according to claim 1 or 2, wherein the first pharmaceutical composition comprises TGF-β in substantial absence of AGF.
4. Use according to claim 1, 2 or 3, wherein the first pharmaceutical composition further comprises one or more binding factors for TGF-β.
5. Use according to any of claims 1 to 4, wherein the second pharmaceutical composition comprises at least IGF-1 as the AGF.
6. Use according to claim 5, wherein the IGF-1 is obtained by extraction from a mammalian milk product, preferably bovine milk or whey.
7. Use according to any of claims 1 to 6, for the preparation of a product for use in the treatment and/or prevention of damage of the intestinal mucosa as a result of chemotherapy or radiotherapy.
8. Use according to claim 7, wherein the first pharmaceutical composition is administered during the period starting at the latest the first day of said chemotherapy or radiotherapy treatment and ending at the latest at the effective end of said treatment.
9. Use according to any of claims 1 to 6, for the preparation of a product for use in the treatment and/or prevention of inflammatory bowel diseases.
10. Use according to any of claims 1 to 9, wherein the first pharmaceutical composition further contains fibres which upon fermentation form more than 15 g of butyrate per 100 g of short chain fatty acids and/or immunoglobulins and/or calcium.
11. Use according to claim 10, wherein the first pharmaceutical composition contains fibres which upon fermentation form more than 15 g of butyrate per 100 g of short chain fatty acids as well as immunoglobulins and calcium.
12. Use according to claim 10 or 11, wherein the fibres are wheat bran fibres.
13. Use according to any of claims 1 to 12, wherein the first pharmaceutical composition further contains at least one member of the group of lactoferrin, fatty acids and antioxidants.
14. Use according to any of claims 1 to 13, wherein the second pharmaceutical composition further contains fibres selected from the group of soluble non-starch polysaccharides, insoluble non-starch polysaccharides, oligosaccharides, resistant starch and mixtures thereof.
15. Use according to any of claims 1 to 14, wherein the second pharmaceutical composition further contains at least one member of the group comprising lactoferrin, glutamine and antioxidants.
16. Product containing a) transforming growth factor β (TGF-β) in substantial absence of insulin-like growth factor 1 (IGF-1), which TGF-β is obtained by extraction from a mammalian milk product and b) anabolic growth factors (AGF) in substantial absence of TGF-β; as combination for sequential administration for treating and/or preventing malfunction or disease of the intestinal mucosa.
17. Pharmaceutical composition containing a) transforming growth factor β (TGF-β) in the substantial absence of insulin-like growth factor 1 (IGF-1) and b) fibres which upon fermentation form more than 15 g of butyrate per 100 g of short chain fatty acids and/or c) immunoglobulins and/or d) calcium.
18. Pharmaceutical composition according to claim 17, which comprises TGF-β in the substantial absence of anabolic growth factors (AGF).
19. Pharmaceutical composition according to claim 17 or 18, containing fibres as well as immunoglobulins and calcium.
20. Pharmaceutical composition according to any of claims 17 to 19, containing fibres in such an amount that 1 to 30 g of fibres per day are administered.
21. Pharmaceutical composition according to any of claims 17 to 20, wherein the fibres are wheat bran fibres.
22. Pharmaceutical composition according to any of claims 17 to 21, wherein the TGF-β is obtained by extraction from a mammalian milk product, preferably bovine milk or whey.
23. Pharmaceutical composition according to claim 22, which further contains one or more binding factors for TGF-β.
24. Pharmaceutical composition according to any of claims 17 to 23, containing TGF β in such an amount that 50 ng to 150 μg TGF-β per day is administered.
25. Pharmaceutical composition according to any of claims 17 to 24, further containing at least one member of lactoferrin, fatty acids and antioxidants.
26. Use of a) transforming growth factor β (TGF-β) in the substantial absence of insulin-like growth factor 1 (IGF-1) and b) fibres which upon fermentation form more than 15 g of butyrate per lOOg of short chain fatty acids and/or c) immunoglobulins and/or d) calcium for preparing a pharmaceutical composition for treatment and/or prevention of malfunction or disease of the intestinal mucosa.
27. Use according to claim 26, wherein TGF-β is applied in the substantial absence of anabolic growth factors (AGF).
28. Use according to claim 26 or 27, for preparing a pharmaceutical composition for treatment and/or prevention of damage of the intestinal mucosa as a result of chemotherapy or radiotherapy.
29. Use according to claim 26 or 27, for preparing a pharmaceutical composition for treatment and/or prevention of inflammatory bowel diseases.
30. Pharmaceutical composition containing a) anabolic growth factors (AGF) in the substantial absence of transforming growth factor-β (TGF-β) and b) fibres selected from the group of soluble non-starch polysaccharides, insoluble non-starch polysaccharides, oligosaccharides, resistant starch and mixtures thereof.
31. Pharmaceutical composition according to claim 30, containing at least insulin-like growth factor-1 (IGF-1) as the AGF.
32. Pharmaceutical composition according to claim 31, wherein the IGF-1 is obtained by extraction from a mammalian milk product, preferably bovine milk or whey.
33. Pharmaceutical composition according to claim 30, 31 or 32, further containing at least one member of the group comprising lactoferrin, glutamine and antioxidants.
-0-0-0-0-0-
EP00971890A 1999-10-06 2000-10-06 Use of tgf beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa Ceased EP1221965A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07100978A EP1779863A1 (en) 1999-10-06 2000-10-06 Use of TGF-Beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/NL1999/000620 WO2001024812A1 (en) 1999-10-06 1999-10-06 USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA
WOPCT/NL99/00620 1999-10-06
PCT/NL2000/000719 WO2001024813A1 (en) 1999-10-06 2000-10-06 Use of tgf beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP07100978A Division EP1779863A1 (en) 1999-10-06 2000-10-06 Use of TGF-Beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa

Publications (1)

Publication Number Publication Date
EP1221965A1 true EP1221965A1 (en) 2002-07-17

Family

ID=19866617

Family Applications (2)

Application Number Title Priority Date Filing Date
EP07100978A Withdrawn EP1779863A1 (en) 1999-10-06 2000-10-06 Use of TGF-Beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa
EP00971890A Ceased EP1221965A1 (en) 1999-10-06 2000-10-06 Use of tgf beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP07100978A Withdrawn EP1779863A1 (en) 1999-10-06 2000-10-06 Use of TGF-Beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa

Country Status (6)

Country Link
EP (2) EP1779863A1 (en)
JP (1) JP2003510367A (en)
CN (2) CN1378458A (en)
AU (2) AU6232899A (en)
BR (1) BR0014563A (en)
WO (2) WO2001024812A1 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3928186A1 (en) * 1989-08-25 1991-03-14 Niehoff Kg Maschf Gripper system for electrical coils - has frame with retractable bolts which locate against flanges of former
FR2827290B1 (en) 2001-07-13 2004-07-09 Pierre Jouan Biotechnologies Sa METHOD FOR OBTAINING A PROTEIN FRACTION ENRICHED IN ACTIVATED FORM TGF-BETA, PROTEIN FRACTION AND THERAPEUTIC APPLICATIONS
GB0229658D0 (en) * 2002-12-20 2003-01-22 Cleeve Richard J Bird feed
TWI356681B (en) * 2003-11-12 2012-01-21 J Oil Mills Inc Body taste improver comprising long-chain highly u
JP5128935B2 (en) 2004-03-31 2013-01-23 ジェネンテック， インコーポレイテッド Humanized anti-TGF-β antibody
US7572474B2 (en) 2005-06-01 2009-08-11 Mead Johnson Nutrition Company Method for simulating the functional attributes of human milk oligosaccharides in formula-fed infants
US8075934B2 (en) 2008-10-24 2011-12-13 Mead Johnson Nutrition Company Nutritional composition with improved digestibility
US7744895B2 (en) * 2005-08-31 2010-06-29 Yamanashi University Methods of treating allergies using TGF-β1 and allergens
WO2007150049A2 (en) * 2006-06-22 2007-12-27 Agennix Incorporated Lactoferrin as a radioprotective agent
US8350006B2 (en) 2008-10-24 2013-01-08 Mead Johnson Nutrition Company Methods for determining the bioactivity of TGF-β in a composition
US8986769B2 (en) 2008-10-24 2015-03-24 Mead Johnson Nutrition Company Methods for preserving endogenous TGF-β
US8367354B2 (en) 2008-10-24 2013-02-05 Mead Johnson Nutrition Company Methods for determining the levels of TGF-β in a composition
SG10201704531XA (en) * 2008-12-08 2017-07-28 Soligenix Inc Topically active steroids for use in radiation and chemotherapeutics injury
JP5552386B2 (en) * 2010-07-09 2014-07-16 株式会社ファンケル L-ascorbic acid-2-phosphate-6-fatty acid lyophilized preparation and cosmetics
US20120171328A1 (en) 2011-01-05 2012-07-05 Dattatreya Banavara Composition comprising heat labile milk proteins and process for preparing same
AU2012261933B2 (en) 2011-06-03 2017-06-15 Xoma Technology Ltd. Antibodies specific for TGF-beta
EP2762497A1 (en) 2013-02-05 2014-08-06 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3620468A1 (en) 2013-02-05 2020-03-11 EngMab Sàrl Method for the selection of antibodies against bcma
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3029068A1 (en) 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
JP7152156B2 (en) 2015-01-14 2022-10-12 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド Treatment of cancer with anti-LAP monoclonal antibodies
ES2820768T3 (en) 2015-04-03 2021-04-22 Xoma Technology Ltd Cancer treatment using TGF-beta and PD-1 inhibitors
EA202092435A3 (en) 2015-08-03 2021-06-30 Энгмаб Сарл MONOCLONAL ANTIBODIES AGAINST BCMA
AU2016308567B2 (en) 2015-08-17 2022-10-27 Janssen Biotech, Inc. Anti-BCMA antibodies, bispecific antigen binding molecules that bind BCMA and CD3, and uses thereof
DK4050034T3 (en) 2016-09-14 2024-06-03 Teneoone Inc CD3-BINDING ANTIBODIES
US11124577B2 (en) 2016-11-02 2021-09-21 Engmab Sàrl Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
KR102745676B1 (en) 2016-12-21 2024-12-24 테네오바이오, 인코포레이티드 Anti-bcma heavy chain-only antibodies
KR102742528B1 (en) 2017-06-20 2024-12-16 테네오바이오, 인코포레이티드 Anti-BCMA heavy chain-only antibody
CN110945026B (en) 2017-06-20 2024-03-19 特纳奥尼股份有限公司 Heavy chain-only anti-BCMA antibody
PL423673A1 (en) * 2017-12-01 2019-06-03 Lewandowska Agata Composition for oral administration, application of the composition in prevention and therapy of mucositis and method for treatment of mucositis
JP7395508B2 (en) 2018-05-16 2023-12-11 ヤンセン バイオテツク，インコーポレーテツド Methods of treating cancer and improving the effectiveness of T cell redirection therapeutics
KR20210032311A (en) 2018-07-20 2021-03-24 테네오바이오, 인코포레이티드 Heavy chain antibody that binds to CD19
CN110051698A (en) * 2019-03-18 2019-07-26 天津大学 The method of enteron aisle probiotics genetic modification based on microencapsulation processing
WO2020206330A1 (en) 2019-04-05 2020-10-08 Teneobio, Inc. Heavy chain antibodies binding to psma
JP2022537931A (en) 2019-06-14 2022-08-31 テネオバイオ， インコーポレイテッド A multispecific heavy chain antibody that binds to CD22 and CD3
US20220251228A1 (en) 2019-07-30 2022-08-11 Shanghai Hansoh Biomedical Co., Ltd. Anti-bcma antibody, antigen-binding fragment thereof and medical use thereof
CA3165274A1 (en) 2019-12-20 2021-06-24 Novartis Ag Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
AU2021263448A1 (en) 2020-04-29 2022-11-24 Teneobio, Inc. Multispecific heavy chain antibodies with modified heavy chain constant regions
CA3214992A1 (en) 2020-04-29 2021-11-04 Teneobio, Inc. Multispecific heavy chain antibodies with modified heavy chain constant regions
TW202208429A (en) 2020-05-11 2022-03-01 比利時商健生藥品公司 Methods for treating multiple myeloma
WO2022006316A1 (en) 2020-06-30 2022-01-06 Teneobio, Inc. Multi-specific antibodies binding to bcma
CR20230398A (en) 2021-02-16 2023-11-15 Janssen Pharmaceutica Nv Trispecific antibody targeting bcma, gprc5d, and cd3
TW202304979A (en) 2021-04-07 2023-02-01 瑞士商諾華公司 USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
TW202309522A (en) 2021-05-11 2023-03-01 美商健生生物科技公司 Methods and compositions for monitoring the treatment of relapsed and/or refractory multiple myeloma
AU2022380722A1 (en) 2021-11-03 2024-06-20 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
CN118020946A (en) * 2024-03-06 2024-05-14 美赞臣婴幼儿营养品技术(广州)有限公司 Nutritional composition for protecting intestinal barrier and/or preventing central nervous system diseases and application thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3206784C2 (en) * 1982-02-25 1985-05-09 Pfrimmer & Co Pharmazeutische Werke Erlangen Gmbh, 8520 Erlangen Glutamine-containing preparations for oral or intravenous administration
EP0269408A3 (en) * 1986-11-26 1989-08-30 Genentech, Inc. Tgf-beta in the treatment of inflammatory disorders
US5147854A (en) * 1990-05-22 1992-09-15 Hoffmann-La Roche Inc. Tgf-b compositions and method
US5824297A (en) * 1990-06-25 1998-10-20 Oncogene Science, Inc. Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
AUPN271295A0 (en) * 1995-05-02 1995-05-25 Gropep Pty Ltd Method of treatment
SE9002732D0 (en) * 1990-08-24 1990-08-24 Kabivitrum Ab PRODUCT CONTAINING GROWTH FACTOR
US5817625A (en) * 1992-09-21 1998-10-06 Oncogene Science, Inc. Methods of prevention of oral mucositis with transforming growth factor beta
US5451411A (en) * 1993-10-15 1995-09-19 University Of Washington Methods and compositions for the oral delivery of therapeutic agents
EP0756828B2 (en) * 1995-08-04 2010-09-22 N.V. Nutricia Nutritional composition containing fibres
EP0852913A1 (en) * 1997-01-14 1998-07-15 Societe Des Produits Nestle S.A. Composition and method for treatment of inflammatory conditions of the gastro-intestinal tract
NL1005677C2 (en) * 1997-03-27 1998-09-29 Campina Melkunie Bv Method for recovering growth factors, or a composition containing one or more growth factors, from milk or a derivative thereof.
DE19757414A1 (en) * 1997-12-23 1999-07-01 Nutricia Nv Fat blend

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0124813A1 *

Also Published As

Publication number Publication date
CN1299766C (en) 2007-02-14
WO2001024812A1 (en) 2001-04-12
CN1626239A (en) 2005-06-15
AU6232899A (en) 2001-05-10
WO2001024813A1 (en) 2001-04-12
EP1779863A1 (en) 2007-05-02
BR0014563A (en) 2002-06-11
AU1063201A (en) 2001-05-10
CN1378458A (en) 2002-11-06
JP2003510367A (en) 2003-03-18

Similar Documents

Publication Publication Date Title
WO2001024813A1 (en) Use of tgf beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa
US8968726B2 (en) Lactoferrin and angiogenin compositions and uses thereof
Aluko Functional foods and nutraceuticals
US6183784B1 (en) Method of ameliorating alimentary tract damage due to chemotherapy or radiation
RU2483735C2 (en) Methods for immune or hematological stimulation, tumour formation or growth inhibition or prevention of malignant tumour, symptoms of malignant tumours or symptoms related to treatment of malignant tumours
EP1411951B1 (en) Enteral compositions for the prevention and/or treatment of sepsis
US5547927A (en) Enteral nutritional product for patients undergoing radiation therapy and/or chemotherapy
KR0136072B1 (en) Nutritional products for people receiving radiation therapy and / or chemotherapy
US5514656A (en) Method of providing enteral nutritional support for patients undergoing radiation therapy and/or chemotherapy
JP4379924B2 (en) Lectin composition and use thereof
JP2006515879A (en) Method for improving nutrient utilization by mammals and compositions for use therein
Triantafillidis et al. Maintenance treatment of Crohn's disease with a polymeric feed rich in TGF-β
RU2198673C2 (en) Medicinal preparation for optimization of mucus viscosity and stimulation of intestine function
US20150174218A1 (en) ANGIOGENIN COMPLEXES (ANGex) WITH ANABOLIC HORMONES FOR IMPROVING BONE HEALTH
Playford et al. Bovine Colostrum: Its Constituents and Uses. Nutrients. 2021; 13: 265
JP7506658B2 (en) Nutritional Composition for the Treatment of Exocrine Pancreatic Insufficiency (EPI)
KR20010112329A (en) Drugs, foods, drinks and feeds containing cocoa component
KR100518126B1 (en) Lectin composition and its use
TW201735942A (en) Composition for inhibiting migration of endotoxin into blood
Mc Donagh et al. Milk and dairy products for better human health
CN113508841A (en) Nutritious morning tea
JP2024539844A (en) Compositions and methods for enhancing intermittent fasting using autophagy inducers
AU689719B2 (en) Method of preventing or treating alimentary tract damage due to chemotherapy or radiation
CN116159068A (en) Novel use of bile acids and/or bile acid receptor agonists
JP2001226285A (en) Small intestinal growth promoting composition

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020402

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CAMPINA B.V.

Owner name: N.V. NUTRICIA

17Q First examination report despatched

Effective date: 20030121

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20070412